Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant <em>Enterobacterales</em>

Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant <em>Enterobacterales</em>

Background: Experience in real clinical practice with ceftazidime-avibactam for the treatment of serious infections due to gram−negative bacteria (GNB) other than carbapenem-resistant <i>Enterobacterales</i> (CRE) is very limited. Methods: We carried out a retrospective multicenter study...

Full description

Bibliographic Details
Main Authors: Antonio Vena, Daniele Roberto Giacobbe, Nadia Castaldo, Annamaria Cattelan, Cristina Mussini, Roberto Luzzati, Francesco Giuseppe De Rosa, Filippo Del Puente, Claudio Maria Mastroianni, Antonio Cascio, Sergio Carbonara, Alessandro Capone, Silvia Boni, Chiara Sepulcri, Marianna Meschiari, Francesca Raumer, Alessandra Oliva, Silvia Corcione, Matteo Bassetti, for the Ceftabuse Study Group
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Antibiotics
Subjects:
carbapenem-sparing regimen
ceftazidime-avibactam
pseudomonas aeruginosa
esbl-producing enterobacterales
nosocomial pneumonia
Online Access:https://www.mdpi.com/2079-6382/9/2/71

Internet

https://www.mdpi.com/2079-6382/9/2/71

Similar Items